EUCTR2007-002015-38-ES进行中（未招募）不适用
ENSAYO CLÍNICO MULTICÉNTRICO, FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO INTRAINDIVIDUALMENTE CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE P144 EN EL TRATAMIENTO TÓPICO DE LA FIBROSIS CUTÁNEA DE PACIENTES CON ESCLEROSIS SISTÉMICAPHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, INTRAINDIVIDUALLY PLACEBO CONTROLLED CLINICAL TRIAL, TO EVALUATE EFFICACY AND SAFETY OF P144 TOPICAL ADMINISTRATION FOR SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS
ISDI0 个研究点目标入组 98 人开始时间: 2007年7月2日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •·Patients male and female >18 < 65 years at time of consent.
- •·History of Systemic sclerosis (including diffuse scleroderma and limited scleroderma) for less than three years of evolution from the onset of cutaneous manifestations.
- •·Symmetric lesions in forearms. The extension of the selected symmetric lesions must be at least 15 cm2.
- •·Stable therapy for at least one month, except in the case of patients under treatment with putative disease modifying agents (immunosupressants like cyclophosphamide, methotrexate or azathioprine) that will need at least three months of stable therapy, without the expectation of treatment modifications during the trial period.
- •·Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol specific procedures are performed.
- •·For female subjects with childbearing potential: use of a known highly effective method of birth control, defined as those which results in a low failure rate: i.e. less 1% per year, (contraceptive pills, intrauterine contraceptive device, implants, vasectomized partner or sexual abstinence), for at least three consecutive months prior to the study, during the study and one month after the end of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·Patients diagnosed of:
- •oSystemic sclerosis sine scleroderma.
- •oLocalized scleroderma.
- •oEosinophilic fascitis, eosinophilia myalgia syndrome.
- •·Any other definable connective tissue disease, such as rheumatoid arthritis, systemic lupus erythematosus, polymyositis, or dermatomyositis.
- •·Clinically significant overlap condition.
- •·Significant existing internal organ damage (Kidney, Cardiovascular disease, Pulmonary disease, Gastrointestinal disease) as defined in Guidelines for clinical trial in systemic sclerosis (scleroderma)
- •·History of skin cancer.
- •·Other skin diseases affecting the treatment area.
- •·Patients with substantial history of environmental exposure to tainted rapeseed oil, vinyl chloride, L- tryptophan, bleomycin, trichoroethylene, or silica.
- •·PUVA therapy within 1 month of study drug initiation.
- •·Concurrent interventional therapy that might independently influence outcome of trial, such as D-penicillamine, cyclosporine, interferon-g or photopheresis.
- •·Topical corticosteroids treatment affecting the selected area.
- •·Cosmetics over the treatment area.
- •·Pregnant or breast-feeding women.
- •·Reasonable expectation that the subject will not be able to satisfactorily complete the study:
- •oHistory of or current psychiatric illness that would interfere with the subject’s ability to comply with protocol requirements or give informed consent.
- •oHistory of alcohol or drug abuse that would interfere with the subject’s ability to comply with protocol requirements.
- •oReceipt of any investigational drug within three months of screening visit.
- •oDocumented noncompliance.
研究者
相似试验
进行中（未招募）
1 期
ENSAYO CLÍNICO MULTICÉNTRICO FASE I/II ALEATORIZADO Y CONTROLADO CON PLACEBO, PARA EVALUACIÓN DE SEGURIDAD Y FACTIBILIDAD DE LA TERAPIA CON DOS DOSIS DISTINTAS DE CÉLULAS TRONCALES MESENQUIMALES AUTÓLOGAS DE TEJIDO ADIPOSO (CETMAD) EN PACIENTES CON ESCLEROSIS MÚLTIPLE SECUNDARIAMENTE PROGRESIVA, QUE NO RESPONDEN ADECUADAMENTE A LOS TRATAMIENTOS REGISTRADOS.EUCTR2008-004015-35-ESFundación Progreso y Salud30
进行中（未招募）
不适用
ENSAYO CLÍNICO DE FASE II, MULTICÉNTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACIÓN DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO Y/O METASTÁSICOEUCTR2008-000225-19-ESGRUPO GETNE
进行中（未招募）
不适用
ENSAYO CLÍNICO, FASE IIIb, MULTICÉNTRICO, DOBLE CIEGO, PARA EVALUAR LA EFICACIA DE VARDENAFILO BUCODISPERSABLE vs PLACEBO, EN PACIENTES CON DISFUNCIÓN ERÉCTIL MAS COMORBILIDAD Y EL IMPACTO EN LA CALIDAD DE VIDA SEXUAL DE SU PAREJA - VADEOPEPacientes con disfunción eréctil que presenten dislipemia, hipertensión, diabetes y/o obesidad.MedDRA version: 11Level: PTClassification code 10061461Term: Disfunción eréctilEUCTR2009-017686-34-ESROLOGY ASSOCIATES S.L.
进行中（未招募）
1 期
Ensayo clínico de fase II prospectivo, multicéntrico, aleatorizado de grupos paralelos, abierto, para estudiar la eficacia, seguridad y tolerabilidad de 2 dosis de ZK 219477 (16 y 12 mg/m2 de área de superficie corporal) en pacientes con cáncer de mama metastásicoEUCTR2005-003216-30-ESSchering AG
进行中（未招募）
不适用
Ensayo Clínico Fase IIa, Multicéntrico, Doble Ciego para Evaluar la Eficacia y Seguridad de dosis bajas de Diazoxida oral en el tratamiento de la Esclerosis MúltipleTratamiento de la Esclerosis Múltiple.MedDRA version: 13Level: LLTClassification code 10063399Term: Esclerosis múltiple remitente-recurrenteEUCTR2010-023048-34-ESEUROTEC PHARMA, S.105